Explore

Rapid Read Rapid Read
US Health Agencies Face Scrutiny Over Vaccine Information Restrictions

US Health Agencies Face Scrutiny Over Vaccine Information Restrictions

Recent actions by US health agencies have sparked concern among scientists and doctors regarding the control over public communication about vaccines. Reports indicate that studies on the safety of vaccines against shingles and Covid were halted by the FDA, and a study on Covid booster effectiveness was stopped by the CDC. These decisions have raised questions about the agencies' influence on scientific discourse and public trust. Michelle Barron, a professor of infectious diseases, emphasized the importance of vaccines and expressed concern over the suppression of scientific studies. The situation is further complicated by executive orders affecting how vaccine-related information is presented, as seen in the case of Elias Kass, a naturopathic physician, who was asked to alter his presentation slides due to CDC guidelines.
AP News AP News
FDA's new playbook: Lots of media announcements but not much rulemaking

FDA's new playbook: Lots of media announcements but not much rulemaking

Health Secretary Robert F. Kennedy Jr. and other health officials have repeatedly announced major changes before any new rules have been drafted
Rapid Read Rapid Read
FDA Faces Criticism Over Blocking Covid Vaccine Study Publication

FDA Faces Criticism Over Blocking Covid Vaccine Study Publication

The FDA is under scrutiny following reports that it blocked the publication of a study affirming the safety of Covid and shingles vaccines. Critics, including a Harvard medical professor, have labeled the action as censorship, suggesting it creates public uncertainty about vaccine safety. The controversy arises amid ongoing efforts by FDA scientists to communicate the safety and efficacy of vaccines to the public. This incident is not isolated, as similar actions have been reported previously, raising questions about transparency and decision-making within the agency.
Trendline Trendline
Pierre Fabre Aligns with FDA for Tabelecleucel Resubmission Pathway

Pierre Fabre Aligns with FDA for Tabelecleucel Resubmission Pathway

Pierre Fabre Aligns with FDA for Tabelecleucel Resubmission Pathway
Trendline Trendline
Mirum Pharmaceuticals Achieves Key Milestone in PSC Treatment with Volixibat

Mirum Pharmaceuticals Achieves Key Milestone in PSC Treatment with Volixibat

Mirum Pharmaceuticals Achieves Key Milestone in PSC Treatment with Volixibat
Trendline Trendline
Gene Therapy Faces Evidence Challenges Amid FDA Decisions

Gene Therapy Faces Evidence Challenges Amid FDA Decisions

Gene Therapy Faces Evidence Challenges Amid FDA Decisions
Trendline Trendline
FDA Approves LANGLARA as Interchangeable Biosimilar for Diabetes Treatment

FDA Approves LANGLARA as Interchangeable Biosimilar for Diabetes Treatment

FDA Approves LANGLARA as Interchangeable Biosimilar for Diabetes Treatment
Trendline Trendline
Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept
Rapid Read Rapid Read
Cellenkos Receives FDA Clearance for New GVHD Treatment Trial

Cellenkos Receives FDA Clearance for New GVHD Treatment Trial

Cellenkos, a biotechnology company, has received FDA clearance to initiate a Phase 1b/2a clinical trial for CK0802, a new treatment for steroid-refractory graft-versus-host disease (GVHD). This condition occurs when donor T cells attack the recipient's organs following a stem cell transplant. Current treatments rely on high-dose steroids, which are often ineffective and leave patients vulnerable to infections. CK0802, a Treg therapy, aims to suppress inflammation and promote immune stability. The trial will evaluate the safety and efficacy of CK0802 in patients who have not responded to steroid therapy.
Rapid Read Rapid Read
FDA Withdraws COVID and Shingles Vaccine Research Findings Over Data Concerns

FDA Withdraws COVID and Shingles Vaccine Research Findings Over Data Concerns

The Food and Drug Administration (FDA) has withdrawn the publication of studies that assessed the safety of COVID-19 and shingles vaccines. According to a spokesperson from the Department of Health and Human Services (HHS), the studies were retracted because the authors made broad conclusions that were not supported by the underlying data. This decision is part of the FDA's effort to maintain the integrity of its scientific process and ensure that all associated work meets high standards. The studies, which were funded by taxpayer money, analyzed millions of patient records and concluded that serious side effects from the vaccines were rare. However, the withdrawal has sparked concerns about the potential censorship of taxpayer-funded science and its impact on public health communication.
Trendline Trendline
FDA Rejection Highlights Challenges in Gene Therapy Approvals

FDA Rejection Highlights Challenges in Gene Therapy Approvals

FDA Rejection Highlights Challenges in Gene Therapy Approvals
Trendline Trendline
Cytokinetics' Myqorzo Achieves Success in Non-Obstructive Hypertrophic Cardiomyopathy Trial

Cytokinetics' Myqorzo Achieves Success in Non-Obstructive Hypertrophic Cardiomyopathy Trial

Cytokinetics' Myqorzo Achieves Success in Non-Obstructive Hypertrophic Cardiomyopathy Trial